Safety and efficacy of frexalimab in relapsing multiple sclerosis: 48-week results from the phase 2 open-label extension

Authors
Category Primary study
Conference10th Congress of the European Academy of Neurology
Year 2024
This article has no abstract
Epistemonikos ID: b77b1dcff5d69cefb4bcb291d1161265ee5653b8
First added on: Jan 10, 2026